Showing 1921-1930 of 10617 results for "".
Diagnosing and Treating Peripheral Arterial Disease
https://reachmd.com/programs/diabetes-discourse/diagnosing-and-treating-peripheral-arterial-disease/4689/People with diabetes are at increasingly higher risk for developing peripheral arterial disease. However, the disease may have no symptoms and often goes undiagnosed. What is the link between PAD and diabetes? Our guest, Dr. Niren Angle, chief of vascular and endovascular surgery at the UnThe Rise in Diagnosis of ACL Injuries in Children
https://reachmd.com/programs/clinicians-roundtable/the-rise-in-diagnosis-of-acl-injuries-in-children/2995/In years past, we understood that children rarely suffered ACL injuries. But we're now learning that this diagnosis, previously reserved for adults, has become increasingly common in children. How can we best counsel a young patient who suffers an ACL injury? Host Dr. Mark Nolan Hill welcomes Dr. MiComparative Effectiveness Research: How to Get There?
https://reachmd.com/programs/heart-matters/comparative-effectiveness-research-how-to-get-there/4735/The Institute of Medicine recently released a list of 100 priority topics for comparative effectiveness research. The first topic on the first page of the report calls for an evaluation of treatment strategies for atrial fibrillation, from surgery or catheter ablation, to pharmacologic therapy. HowReforming the FDA's Drug Approval Process
https://reachmd.com/programs/heart-matters/reforming-the-fdas-drug-approval-process/4285/It takes a substantial measure of time, money and manpower to bring a new drug from the bench to the marketplace. One key aspect of this sequence is the drug approval process, overseen by the Food and Drug Administration (FDA). Host Dr. Jack Lewin welcomes Dr. Mark McClellan, director of the EngelbeWarranties, Integration and Enduring Innovation at Geisinger
https://reachmd.com/programs/heart-matters/warranties-integration-and-enduring-innovation-at-geisinger/4776/At some point during the health reform debate, you've probably heard President Obama and others recognize the work of the Geisinger Health System. Through a variety of mechanisms -- among others, charging a flat fee for certain surgical procedures and other high-volume episodes of care, and workingNeck and Back Pain: When Should You Refer Your Patients to a Neurosurgeon?
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/when-to-refer-neck-and-back-pain-patients-to-a-neurosurgeon/8478/Dr. Patrick Connolly discusses when to consider referring patients to neurosurgeons for neck and back pain, and the best surgical options available.Beyond the "Barebones" of Osteoporosis Management
https://reachmd.com/programs/clinicians-roundtable/beyond-the-barebones-of-osteoporosis-management/7214/Dr. Prathima Setty welcomes Dr. Ethel Siris, the Madeline C. Stabile Professor of Clinical Medicine in the Department of Medicine, College of Physicians and Surgeons of Columbia University, and the Director of the Toni Stabile Osteoporosis Center of the Columbia University Medical Center. Their discHeated Intraperitoneal Chemotherapy (HIPEC) for Advanced Abdominal Cancers
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/heated-intraperitoneal-chemotherapy-hipec-for-advanced-abdominal-cancers/7091/Heated/Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is one of the most innovative treatments available today for complex abdominal cancers. What is it? Who is a candidate? And, what are the expected outcomes for our patients? Host Dr. Lee Freedman welcomes Dr. Giorgos Karakousis, Assistant ProfSuccessful Aging in a High-Tech World
https://reachmd.com/programs/clinicians-roundtable/successful-aging-in-a-high-tech-world/2795/What are the greatest challenges as we age? Will healthcare and lifestyle improve concurrently? In one of the first conferences of its kind, the UCLA Center on Aging presented a one-day symposium featuring a discussion among national academic and industry leaders about the interface between new techTracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
https://reachmd.com/programs/project-oncology/lineage-infidelity-pediatric-b-all-ash/39976/New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition reveals how chemotherapy and immunotherapy may drive the emergence of CD-19–negative, myeloid-like subclones in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Mr. Ryan Quigley sits down with Dr. Kath